Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 871 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

NTRR to commence Pure Plus clinical trial

The trial follows the shipment of initial test batch as well as Pure Plus from the manufacturer to a laboratory for a highly specialised Bio-energy infusion that enhnaces

Mission Pharmacal buys Ferndale Eletone cream

The US Food and Drug Administration approved Eletone Cream is a non-steroidal, barrier cream for the long term treatment of atopic dermatitis, an inflammatory, chronically relapsing, non-contagious and

Medicago to invest in pilot production facility

The new investment includes capital expenditures and labour costs, as well as preclinical studies for a rabies vaccine and other products. The company anticipates this investment to enhance

Apricus inks Nitromist rights deal with NovaDel

The FDA-approved NitroMist is a nitrate vasodilator indicated for acute relief of an attack or acute prophylaxis of angina pectoris (chest pain) due to coronary artery disease. Developed

FDA removes hold on Idenix hepatitis drug

IDX184 is a pan-genotypic oral nucleotide polymerase inhibitor, used for the treatment of hepatitis C virus (HCV) infection. In September 2010, FDA has issued a clinical hold as

Dalfampridine found to improve motor function

Dalfampridine, also known as 4-aminopyridine, is the active chemical ingredient in Ampyra (dalfampridine) extended release tablets, 10 mg. In the study, researchers evaluated functional improvement using a battery